• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    4/13/22 1:35:51 PM ET
    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Kaleido Biosciences (NASDAQ:KLDO) shares moved upwards by 105.3% to $0.35 during Wednesday's regular session. Kaleido Biosciences's stock is trading at a volume of 170.1 million shares as of 13:30 EST. This is 20116.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.0 million.
    • Antares Pharma (NASDAQ:ATRS) shares increased by 49.19% to $5.58. As of 13:30 EST, this security is trading at a volume of 105.0 million shares, making up 13080.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $949.1 million.
    • Sierra Oncology (NASDAQ:SRRA) stock rose 38.62% to $54.78. Trading volume for Sierra Oncology's stock is 8.6 million as of 13:30 EST. This is 694.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.2 billion.
    • Biofrontera (NASDAQ:BFRI) shares increased by 30.81% to $4.84. Biofrontera's stock is trading at a volume of 19.9 million shares as of 13:30 EST. This is 831.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $82.7 million. The company's, Q4 earnings came out 3 days ago.
    • Turning Point (NASDAQ:TPTX) stock moved upwards by 29.77% to $32.17. The current volume of 1.7 million shares is 338.3% of Turning Point's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.5 billion.
    • Exscientia (NASDAQ:EXAI) stock rose 21.01% to $14.95. Trading volume for Exscientia's stock is 176.3K as of 13:30 EST. This is 73.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.8 billion.

    Losers

    • NanoString Technologies (NASDAQ:NSTG) stock decreased by 31.3% to $22.65 during Wednesday's regular session. As of 13:30 EST, NanoString Technologies's stock is trading at a volume of 4.9 million, which is 950.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.0 billion.
    • PolarityTE (NASDAQ:PTE) shares fell 29.26% to $0.27. Trading volume for PolarityTE's stock is 21.2 million as of 13:30 EST. This is 404.2% of its average full-day volume over the last 100 days. The company's market cap stands at $24.3 million.
    • Fulcrum Therapeutics (NASDAQ:FULC) shares declined by 20.26% to $13.07. Fulcrum Therapeutics's stock is trading at a volume of 1.4 million shares as of 13:30 EST. This is 283.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $531.1 million.
    • Bio-Path Holdings (NASDAQ:BPTH) shares fell 15.96% to $3.16. Trading volume for Bio-Path Holdings's stock is 251.6K as of 13:30 EST. This is 450.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.6 million.
    • Histogen (NASDAQ:HSTO) shares declined by 15.89% to $0.35. The current volume of 10.8 million shares is 494.2% of Histogen's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $17.4 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares decreased by 14.35% to $1.91. As of 13:30 EST, Aeglea BioTherapeutics's stock is trading at a volume of 1.0 million, which is 203.2% of its average full-day volume over the last 100 days. The company's market cap stands at $94.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $ATRS
    $BFRI
    $BPTH

    CompanyDatePrice TargetRatingAnalyst
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Fulcrum Therapeutics Inc.
    $FULC
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    Fulcrum Therapeutics Inc.
    $FULC
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    Fulcrum Therapeutics Inc.
    $FULC
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    Fulcrum Therapeutics Inc.
    $FULC
    9/12/2024$4.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TESTOSTERONE UNDECANOATE issued to ANTARES PHARMA INC

    Submission status for ANTARES PHARMA INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/30/22 12:07:58 PM ET
    $ATRS
    Medical/Dental Instruments
    Health Care

    September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

    For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

    9/7/21 4:11:11 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

    SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    3/26/26 6:37:35 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 1-A filed by Bio-Path Holdings Inc.

    1-A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    3/25/26 2:24:02 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    3/19/26 9:30:07 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

    CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (NASDAQ:FULC), a leader in advancing therapies for underserved patient populations, today announced a new partnership designed to help streamline and expedite emergency department (ED) care for people living with sickle cell disease (SCD) through rapid access to patient-specific care plans. Individuals living with SCD, an inherited blood disorder,

    3/19/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Weber Kevin Daniel

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:33:07 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:31:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:30:26 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Fulcrum Therapeutics

    Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy

    11/24/25 8:30:36 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Fulcrum Therapeutics from Neutral to Buy and set a new price target of $12.00 from $4.00 previously

    7/29/25 11:36:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote

    2/24/26 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Exscientia Plc

    SC 13G/A - Exscientia plc (0001865408) (Subject)

    11/22/24 9:11:55 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Exscientia Plc

    SC 13D/A - Exscientia plc (0001865408) (Subject)

    11/22/24 8:00:16 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ATRS
    $BFRI
    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

    Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jones as Chief Commercial Officer (CCO), starting August 25, 2025. In this role, Mr. Jones will oversee the Company's commercial functions, including sales, marketing, and market access. He will report directly to CEO Dr. Hermann Luebbert. This strengthening of the Company's management follows the recent announcement of an agreement to acquire all rights and assets related to Ameluz® and RhodoLED® for the US market, including the FDA approval and al

    8/11/25 4:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

    Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

    8/8/24 7:39:25 AM ET
    $EXAI
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care